Strategies to target Mbd2 for prevention of DC, macrophage/monocyte, or CEC exacerbation of intestinal inflammation may enable future development of innovative therapies to help control excessive inflammatory responses that define conditions such as IBD. Here, MBD2 is linked to inflammatory bowel disease.